Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 4/20 | 0.47 |
| ▸ | FPR3 | P25089 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | GRK2 | P25098 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1688815 | 0.91 | POLB (0.47) | FPR2FPR3HPGDKMT2AMEN1 | |
| SCHEMBL1039226 | 0.85 | MAPT (0.47) | KMT2AMEN1POLBALDH1A1MAPT | |
| SCHEMBL28477283 | 0.84 | FPR2 (0.47) | FPR2FPR3HPGDKMT2AMEN1 | |
| SCHEMBL5807704 | 0.83 | POLB (0.42) | FPR2FPR3HPGDNPC1RAB9A | |
| SCHEMBL9135786 | 0.83 | MAPT (0.52) | FPR2KMT2AMEN1NPC1RAB9A | |
| SCHEMBL18740367 | 0.83 | CTNNB1 (0.46) | KMT2AMEN1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL303932 | 0.83 | PKM (0.46) | HPGDKMT2AMEN1NPC1RAB9A | |
| SCHEMBL5000420 | 0.82 | HPGD (0.57) | HPGDKMT2AMEN1NPC1RAB9A | |
| SCHEMBL9135725 | 0.82 | MAPT (0.53) | KMT2AMEN1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL846596 | 0.82 | MAPT (0.44) | HPGDKMT2AMEN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10717738-B2 | Pyrimidinone and its derivatives inhibiting factor XIa | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-07-21 | — | — | US | disclosed |
| EP-3290413-B9 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO PHARMACEUTICAL CO (JP) | 2020-04-29 | — | — | EP | disclosed |
| EP-3290413-B1 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO PHARMACEUTICAL CO (JP) | 2019-11-13 | — | — | EP | disclosed |
| EP-3290413-A1 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO Pharmaceutical Co., Ltd. (JP) | 2018-03-07 | — | — | EP | disclosed |
| EP-2794597-B1 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO PHARMACEUTICAL CO (JP) | 2017-11-15 | — | — | EP | disclosed |
| US-20170305917-A1 | COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-10-26 | — | — | US | disclosed |
| US-9732085-B2 | Pyridinone and pyrimidinone derivatives as factor Xia | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-08-15 | — | — | US | disclosed |
| US-20150152112-A1 | COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-06-04 | — | — | US | disclosed |
| EP-2794597-A1 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO Pharmaceutical Co., Ltd. (JP) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013093484-A1 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-06-27 | — | — | WO | disclosed |
| US-20080227858-A1 | Inhibitors of matrix metalloproteinase | GLAXO GROUP LIMITED | 2008-09-18 | — | — | US | disclosed |
| US-20080227858-A1 | Inhibitors of matrix metalloproteinase | GLAXO GROUP LIMITED | 2008-09-18 | — | — | US | disclosed |
| US-7375248-B2 | Inhibitors of matrix metalloproteinase | GLAXO GROUP LIMITED (GB) | 2008-05-20 | — | — | US | disclosed |
| US-7375248-B2 | Inhibitors of matrix metalloproteinase | GLAXO GROUP LIMITED (GB) | 2008-05-20 | — | — | US | disclosed |
| WO-2004113279-A1 | INHIBITORS OF MATRIX METALLOPROTEINASE | GLAXO GROUP LIMITED (GB) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152112-A1 | COMPOUNDS | F11, F12, F10 | FPR2 1616/4885FPR3 1102/4885HPGD 393/4885 |
| US-20170305917-A1 | COMPOUNDS | F11, F12, F10 | FPR2 1616/4885FPR3 1102/4885HPGD 393/4885 |
| US-20080227858-A1 | Inhibitors of matrix metalloproteinase | MMP9, MMP13, MMP2 | FPR2 3235/4885FPR3 1147/4885HPGD 2039/4885 |
| US-10717738-B2 | Pyrimidinone and its derivatives inhibiting factor XIa | F11, TFPI, F10 | FPR2 900/4885FPR3 1091/4885HPGD 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.